$418 Million is the total value of VR Adviser, LLC's 16 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 112.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CNST | CONSTELLATION PHARMACEUTICALS INC | $120,707,000 | -4.4% | 4,016,873 | 0.0% | 28.90% | -15.5% | |
| TRILLIUM THERAPEUTICS INC | $54,931,000 | +100.2% | 6,790,000 | 0.0% | 13.15% | +77.0% | ||
| ALT | New | ALTIMMUNE INC | $48,195,000 | – | 4,500,000 | +100.0% | 11.54% | – |
| RLMD | Sell | RELMADA THERAPEUTICS INC | $29,913,000 | +4.1% | 668,440 | -20.7% | 7.16% | -8.0% |
| SURF | New | SURFACE ONCOLOGY INC | $25,439,000 | – | 3,877,895 | +100.0% | 6.09% | – |
| KROS | New | KEROS THERAPEUTICS INC | $25,218,000 | – | 672,306 | +100.0% | 6.04% | – |
| VXRT | New | VAXART INC | $24,470,000 | – | 2,765,000 | +100.0% | 5.86% | – |
| MYOV | New | MYOVANT SCIENCES LTD | $17,424,000 | – | 845,000 | +100.0% | 4.17% | – |
| MRNS | Sell | MARINUS PHARMACEUTICALS INC | $14,545,000 | +10.2% | 5,726,540 | -11.9% | 3.48% | -2.6% |
| NARI | New | INARI MEDICAL INC | $11,383,000 | – | 235,000 | +100.0% | 2.73% | – |
| KURA | New | KURA ONCOLOGY INC | $9,373,000 | – | 575,000 | +100.0% | 2.24% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $9,273,000 | – | 625,710 | +100.0% | 2.22% | – |
| AVDL | AVADEL PHARMACEUTICALS PLCspons adr | $8,547,000 | +1.8% | 1,057,827 | 0.0% | 2.05% | -10.0% | |
| ADAP | New | ADAPTIMMUNE THERAPEUTICSspons adr | $7,827,000 | – | 781,940 | +100.0% | 1.87% | – |
| ETNB | Sell | 89BIO INC | $5,802,000 | -75.9% | 291,140 | -69.4% | 1.39% | -78.7% |
| SRRA | Sell | SIERRA ONCOLOGY INC | $4,585,000 | -4.9% | 378,888 | -22.8% | 1.10% | -15.9% |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -113,140 | -100.0% | -0.22% | – |
| SPRO | Exit | SPERO THERAPEUTICS INC | $0 | – | -474,015 | -100.0% | -1.04% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -2,586,537 | -100.0% | -2.41% | – |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -994,381 | -100.0% | -2.63% | – |
| VSTM | Exit | VERASTEM INC | $0 | – | -3,720,930 | -100.0% | -2.66% | – |
| MRSN | Exit | MERSANA THERAPEUTICS INC | $0 | – | -2,623,903 | -100.0% | -4.14% | – |
| TXG | Exit | 10X GENOMICS INC | $0 | – | -300,000 | -100.0% | -5.06% | – |
| INO | Exit | INOVIO PHARMACEUTICALS INC | $0 | – | -2,900,000 | -100.0% | -5.84% | – |
| AXSM | Exit | AXSOME THERAPEUTICS INC | $0 | – | -810,000 | -100.0% | -12.91% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
| VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
| RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
| GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
| ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
| MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
| CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
| AFFIMED N V | 8 | Q3 2023 | 1.1% |
| INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.